Hims & Hers Health, Inc. (NYSE:HIMS) Insider Patrick Harrison Carroll Sells 23,287 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the sale, the insider now directly owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Hims & Hers Health Stock Down 9.3 %

Shares of HIMS opened at $31.46 on Wednesday. The stock has a fifty day simple moving average of $38.72 and a two-hundred day simple moving average of $28.49. The company has a market capitalization of $6.99 billion, a PE ratio of 71.49 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after buying an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health in the fourth quarter valued at about $41,104,000. Finally, Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on HIMS shares. Citigroup reissued a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.